Sotera Health (NASDAQ:SHC) Shares Sold by Phocas Financial Corp.

Phocas Financial Corp. cut its holdings in shares of Sotera Health (NASDAQ:SHC) by 85.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,593 shares of the company’s stock after selling 248,619 shares during the period. Phocas Financial Corp.’s holdings in Sotera Health were worth $596,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of SHC. Blue Trust Inc. grew its stake in Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock worth $25,000 after purchasing an additional 1,140 shares in the last quarter. True Wealth Design LLC bought a new position in Sotera Health during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC grew its position in shares of Sotera Health by 37.5% in the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after acquiring an additional 1,121 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $91,000. Finally, Oak Thistle LLC acquired a new stake in shares of Sotera Health during the 4th quarter valued at approximately $222,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Trading Up 1.9 %

Sotera Health stock opened at $13.73 on Wednesday. The firm has a 50-day moving average price of $13.48 and a two-hundred day moving average price of $14.54. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of 54.92 and a beta of 1.91. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91.

Wall Street Analyst Weigh In

SHC has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective for the company. Citigroup boosted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Barclays cut their target price on shares of Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.08.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.